NEW YORK, May 18, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, the company's chairman and CEO, will be presenting at the Seventh Annual Neurotech Investing and Partnering Conference.
The title of Dr. Chain's presentation is "Prefibrillar Tau Neoepitopes Offer Attractive Targets for Active and Passive Immunotherapy." His presentation will take place on May 21st at the Intercontinental Hotel in Boston from 10:15-11:30 AM (EDT), as part of the session entitled "Alzheimer's and Cognitive Disorders."
"Intellect Neurosciences is at the forefront of Alzheimer's research, with a rich pipeline and intellectual property portfolio and licensed products in late-stage clinical development," said Dr. Chain. "We embrace opportunities like this one and realize they are essential toward raising additional awareness of our technology, our work in developing ground-breaking treatments for Alzheimer's and other devastating neurodegenerative diseases."
About The Neurotech Investing and Partnering Conference
The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.
About Intellect Neurosciences
Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
The company currently is developing products based on three platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology, which underlies a product in Phase 3 clinical trials and is licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, a humanized monoclonal antibody being developed by the company as an antibody dug conjugate (ADC). IN-N01-OX2 is the first candidate to emerge from the company's CONJUMAB-A platform technology, which is based on a novel application of antibody drug conjugates in which the antibody is chemically conjugated to a small molecule (OX2) that has potent neuroprotective properties both as an antioxidant and inhibitor of protein aggregation. RECALL-VAX is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01 and RVO2, which target beta amyloid and delta tau protein, respectively, and RVO3, which is a combination of the two.
The company recently licensed OX1, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-‐looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-‐128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, which was filed on May 14, 2012.
JQA Partners, LLC
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved